EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients

Daniele Lorenzini iD, Gabriella Gaudioso, Alessandro Scardoni iD, Lorenzo Blandi, Alessandro Del Gobbo, Paola Rafaniello Raviele, Stefano Ferrero, Silvio M Veronese, Calogero Lauricella, Fabio Pagni, Davide Seminati iD, Monica Miozzo und 35 weitere

Tumori Journal · 2025

DOI: 10.1177/03008916251341996 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Tumori Journal, 2025. Verfasst von Daniele Lorenzini und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Molecular Targeted Therapy, Lung Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for in-depth simultaneous analysis of multiple genes, thereby streamlining the diagnostic process in LUAD. Despite this, the implementation of NGS testing in both the US and Europe remains suboptimal.

Aims

In compliance with a decree issued by the Italian Ministry of Health, Lombardy Region recently launched an initiative to implement NGS testing in patients with advanced LUAD. In this context, a real-world prospective observational study was planned to assess the efficacy of the regional network of molecular laboratories in testing nine biomarkers ( KRAS p.G12C, EGFR , BRAF, HER2, MET mutations; ALK , ROS1 , NTRK1-3 , RET rearrangements), for on-label molecularly targeted drugs.

Results

In 2023, out of the 2784 advanced/metastatic LUAD patients expected in Lombardy, 2343 (84.2%) were successfully evaluated with an NGS panel including all the nine biomarkers for on-label drugs. Actionable aberrations were identified in 45.5% of the patients (1068/2343), predominantly involving EGFR , KRAS , and ALK genes.

Conclusion

Our data provide evidence that establishing a structured network of NGS hubs is mandatory to ensure access of advanced LUAD patients to molecularly targeted treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungMolecular Targeted TherapyLung NeoplasmsHumansHigh-Throughput Nucleotide SequencingFemaleMutationMaleAnaplastic Lymphoma KinaseMiddle AgedProspective StudiesAgedErbB ReceptorsProto-Oncogene Proteins B-rafAdenocarcinoma of LungProto-Oncogene Proteins p21(ras)ItalyErb-b2 Receptor Tyrosine KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins

Stichwörter der Autor:innen

Lung adenocarcinomaNGSprecision oncologytarget therapy

Substanzen

Biomarkers, TumorAnaplastic Lymphoma KinaseErbB ReceptorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Erb-b2 Receptor Tyrosine KinasesProtein-Tyrosine KinasesProto-Oncogene ProteinsALK protein, humanROS1 protein, human

Autor:innen und Institutionen

  • Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Division of Clinical Pathology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
  • Welfare General Directorate, Regione Lombardia, Milan, Italy.
  • Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Lombardia, Italy.
  • Division of Pathology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

ORCID-Profile: Daniele Lorenzini, Alessandro Scardoni, Davide Seminati, William Vermi, Silvia Uccella, Giancarlo Pruneri

Zitieren

APA

Lorenzini, D., Gaudioso, G., Scardoni, A., Blandi, L., Del Gobbo, A., Rafaniello Raviele, P., Ferrero, S., Veronese, S. M., Lauricella, C., Pagni, F., Seminati, D., Miozzo, M., Pesenti, C., Gianelli, U., Buiatiotis, S., Fumagalli, C., Guerini Rocco, E., Rappa, A., Barberis, M., …, & Pruneri, G. (2025). Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients. Tumori Journal. https://doi.org/10.1177/03008916251341996

Vancouver

Lorenzini D, Gaudioso G, Scardoni A, Blandi L, Del Gobbo A, Rafaniello Raviele P, et al. Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients. Tumori Journal. 2025. doi:10.1177/03008916251341996

BibTeX
@article{Lorenzini2025,
  author = {Lorenzini, Daniele and Gaudioso, Gabriella and Scardoni, Alessandro and Blandi, Lorenzo and Del Gobbo, Alessandro and Rafaniello Raviele, Paola and Ferrero, Stefano and Veronese, Silvio M and Lauricella, Calogero and Pagni, Fabio and Seminati, Davide and Miozzo, Monica and Pesenti, Chiara and Gianelli, Umberto and Buiatiotis, Simona and Fumagalli, Caterina and Guerini Rocco, Elena and Rappa, Alessandra and Barberis, Massimo and Fusco, Nicola and Ranghiero, Alberto and La Rosa, Stefano and Sessa, Fausto and Furlan, Daniela and Sahnane, Nora and Patriarca, Carlo and Cangi, Maria Giulia and Lume, Alessandra and Doglioni, Claudio and Ponzoni, Maurilio and Vermi, William and Novali, Mauro and Paulli, Marco and Boveri, Emanuela and Terracciano, Luigi and Uccella, Silvia and Destro, Annarita and Tamborini, Elena and Perrone, Federica and Pasotti, Fabio and Agustoni, Francesco and De Braud, Filippo and Grossi, Francesco and Siena, Salvatore and Curigliano, Giuseppe and Buoro, Sabrina and Pruneri, Giancarlo},
  title = {Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients},
  journal = {Tumori Journal},
  year = {2025},
  doi = {10.1177/03008916251341996}
}
Kostenlos starten →